CancerNCT07751783

Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations

A study testing structured exercise training in people with Cancer and Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), run by Kaohsiung Medical University Chung-Ho Memorial Hospital at 1 site in Taiwan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of this study is to establish a safe and systematic exercise assessment and prescription program for cancer survivors. It can be challenging for cancer patients to start exercising due to various health risks, so this study aims to create a personalized and easily reproducible workflow. Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer (Non-Small Cell)
What is being tested?: structured exercise training
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 150 participants
Where: 1 siteTaiwan
Study dates: 12 Mar 2026to 31 Aug 2027
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Aged 18 to 80 years.
Cancer Cohorts: Pathologically confirmed diagnosis of AJCC TNM stage I-III, and having completed curative-intent treatment (including surgery ± adjuvant chemotherapy/radiotherapy, etc) for at least 2 months.
Cancer cohort must have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.
Ability to comply with weekly structured exercise training (3-4 professionally supervised sessions per week) and willingness to accept telephone follow-ups or report exercise status via exercise logs/wearable devices.
Self-reported failure to meet the following physical activity guidelines within the past 3 months: at least 150 minutes of moderate-intensity aerobic exercise per week OR at least 75 minutes of vigorous-intensity aerobic exercise per week; AND no regular resistance training (≥ 2 sessions per week) within the past 3 months.

Who cannot join

Cardiovascular instability: History of acute coronary syndrome (ACS), myocardial infarction (MI), acute exacerbation of heart failure, or hospitalization for heart failure within the past 3 months; unstable angina; uncontrolled arrhythmia; or uncontrolled hypertension (resting blood pressure > 180/110 mmHg).
Hypoxemia: Resting oxygen saturation (SpO2) < 90%.
Metabolic instability: Severe hypoglycemic event or diabetic ketoacidosis (DKA) within the past 3 months.
Musculoskeletal or neurological risks: Unstable bone metastasis or bone metastasis with a high risk of fracture; recent major fracture or orthopedic surgery where weight-bearing is not yet permitted; or other severe neuromuscular diseases that compromise the safety of exercise.
Hematological risks: Thrombocytopenia (Platelet count < 50,000/μL), severe anemia (Hemoglobin [Hb] < 8 g/dL), or neutropenia (Absolute Neutrophil Count [ANC] < 1,000/μL).
Deemed unsuitable for exercise intervention as determined by clinical assessment from the attending physician or study investigator.
Concurrent participation in other formal exercise or weight-loss intervention programs.
Inability to comprehend or complete the informed consent form, or inability to comply with the study procedures.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ko-Long Lin, PhD contact

886-978-862-831

klin967@gmail.com

Taiwan1 site, 1 recruiting

Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
Ko-Long Lin, PhD, 886-978-862-831, klin967@gmail.com
Recruiting

Other trials in Taiwan

About this study

Official title: A Program for the Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations

Participants will undergo a comprehensive health and fitness evaluation led by a study physician. This evaluation includes:

A review of medical history and cardiovascular risk.
Functional physical fitness tests.
Cardiopulmonary Exercise Testing (CPET) to carefully evaluate heart and lung function during physical exertion.
A musculoskeletal ultrasound, if deemed necessary. Based on these combined results, the medical team will determine each participant's exercise risk level and design a personalized exercise prescription. Participants will then be assigned to an appropriate and safe exercise setting.

To ensure safety and maximize health benefits, the study includes a continuous tracking system. Participants will report their exercise progress every 4 weeks and undergo a full reassessment every 3 months. The medical team will use this feedback to safely adjust the participant's risk level and exercise prescription over time.

Read the detailed description

This study is designed as a single-arm, open-label interventional research project. The primary objective is to establish and implement a systematic, institution-based exercise prescription protocol tailored for cancer survivors.

The clinical pathway initiates with patient referral and preliminary screening conducted by collaborating physicians or case managers. Eligible participants then undergo a physiatrist-led, multi-faceted pre-exercise evaluation. This comprehensive assessment integrates a medical history review, cardiovascular risk profiling, functional physical fitness testing, and Cardiopulmonary Exercise Testing (CPET). Additionally, musculoskeletal ultrasound examinations are performed when deemed clinically necessary to objectively evaluate the participant's physical condition.

Based on the integrated assessment results, physiatrists stratify participants into high, moderate, or low exercise risk categories. Individualized exercise prescriptions are then formulated according to the assigned risk level, detailing the required exercise modalities-including aerobic exercise, resistance training, and flexibility exercises-as well as the specific intensity, frequency, duration, and safety precautions.

During the implementation phase, participants execute the prescribed exercise program while utilizing standardized weekly training logs to record their progress. The protocol incorporates an adverse event reporting and data feedback mechanism to ensure continuous safety monitoring and intervention quality. To maintain a dynamic care model, clinical data collection and comprehensive reassessments occur at three distinct time points: baseline (T0), the third month of the intervention (T1), and the sixth month of the intervention (T2). These periodic three-month re-evaluations facilitate the continuous adjustment of both the risk stratification and the personalized exercise prescription, ensuring the intervention remains safe, accurate, and effective.

Conditions: Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer (Non-Small Cell), Liver Cancer, Adult, Cancer Survivor
Being tested: structured exercise training
Keywords: exercise, Cardiopulmonary Exercise Testing, cancer, Exercise prescription, Aerobic exercise, resistance exercise
Medical subject headings: Neoplasms, Colonic Neoplasms, Breast Neoplasms, Lymphoma, Multiple Myeloma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

structured exercise trainingOther
This study utilizes a "Personalized Precision Exercise Training Program." Following baseline Cardiopulmonary Exercise Testing (CPET) and comprehensive fitness assessments, physicians prescribe individualized regimens adhering to ACSM guidelines for cancer survivors, applying the FITT principle:
- Aerobic Exercise: 3-5 days/week at moderate intensity, tailored to treatment tolerance. ≥30 mins/session, flexibly adjusted for treatment side effects. Focuses on rhythmic activities (walking, cycling).
- Resistance Training: 2-3 days/week (48h rest per muscle group) at 60-80% 1-RM or a load for 6-15 reps. Employs progressive overload without requiring muscular failure. Involves 8-10 major muscle groups; ≥1 set/exercise, ≥6 reps/set, with ≥60s rest between sets. Modalities adapt to patient status.
- Flexibility Training: ≥2-3 days/week (up to daily). Static stretches (10-30s hold, 2-4 reps, stretching to mild discomfort but avoiding pain) covering all major muscles.

Study groups in NCT07751783
Study group	Role	What they receive
Experimental group	Experimental	structured exercise intervention group Receives: Other: structured exercise training

What is being measured

The primary outcome is the main question the study is designed to answer.

Dominant Handgrip Strength Test
The participant is evaluated in a seated or standing position with the shoulder adducted, the elbow flexed at approximately 90 degrees, and the forearm and wrist in a neutral position. Using a calibrated handgrip dynamometer, the participant performs a maximal voluntary contraction (MVC) with the dominant hand for approximately 3 seconds. The test is repeated 3 times with at least a 30-second rest interval between trials. The highest value obtained from the three trials is recorded as the final result.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
30-Second Arm Curl Test
The participant sits in a chair with their back straight and feet flat on the floor, holding a standard dumbbell in the dominant hand (8 lbs / 3.63 kg for males; 5 lbs / 2.27 kg for females). The participant performs repeated full elbow flexion and extension movements over a 30-second period while maintaining shoulder stability. The total number of correctly completed repetitions within the full range of motion is recorded.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
30-Second Chair Stand Test
Using a standard-height chair without armrests, the participant sits with arms crossed over the chest and their back resting against the backrest. Upon the start signal, the participant repeatedly rises to a full standing position and returns to a fully seated position within a 30-second timeframe. The total number of completed stands is recorded.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
Single-Leg Stance Test
The participant places both hands on their hips and stands on the dominant leg with the contralateral leg lifted off the floor. Timing commences with the participant's eyes open and focused straight ahead, and ceases when any of the following compensatory movements occur: the arms are moved from the hips, the lifted leg moves (toward or away from the stance leg, or touches the floor), the stance foot shifts or lifts, or a loss of balance is observed. The test is repeated 3 times with at least a 30-second rest interval between trials. The average duration of the three trials is recorded as the final result.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
6-Minute Walk Distance
This outcome measures the maximal distance a participant can travel in 6 minutes on a hard, flat surface. The total distance is recorded in meters (m). Higher values indicate better cardiopulmonary endurance and functional mobility.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
Peak Oxygen Consumption (Peak VO2)
Peak oxygen consumption (Peak VO2) is determined through Cardiopulmonary Exercise Testing (CPET). It represents the highest rate of oxygen uptake achieved by the participant during the exercise test. The results are measured and reported in milliliters per kilogram per minute (mL/kg/min).
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
Peak Work Rate
Peak work rate is determined through a symptom-limited Cardiopulmonary Exercise Testing (CPET) using a progressive, incremental ramp protocol on a stationary cycle ergometer. It represents the maximum mechanical power output that the participant can achieve and sustain immediately prior to reaching volitional exhaustion or clinical symptom limitation. The result is measured and reported in Watts (W).
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)

Secondary outcomes (3)

Short Form-36 (SF-36)
The SF-36 is a 36-item patient-reported questionnaire that measures health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored on a scale from 0 to 100. Higher scores indicate a more favorable health state and better quality of life.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
Functional Assessment of Cancer Therapy-General (FACT-G)
The FACT-G is a 27-item questionnaire designed to measure health-related quality of life in patients receiving cancer therapy. It assesses four primary domains: Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). The subscale scores are summed to yield a total score ranging from 0 to 108, with higher scores representing a better quality of life and lower symptom burden.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)
Brief Fatigue Inventory (BFI)
The BFI is a 9-item questionnaire used to rapidly assess the severity of fatigue and its impact on daily functioning, particularly in cancer patients. Patients rate their fatigue severity (at its "worst," "usual," and "now" over the past 24 hours) and the extent to which fatigue interferes with six domains of daily life (general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life). All items are scored on an 11-point numeric rating scale from 0 (no fatigue / does not interfere) to 10 (as bad as you can imagine / completely interferes). A global fatigue score is calculated as the mean of all answered items, ranging from 0 to 10, with higher scores indicating more severe fatigue and greater interference with daily life.
Measured: Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

12 Mar 202631 Aug 2027

First posted7 Aug 2026
Study start12 Mar 2026
Primary completion30 Jun 2027 (estimated)
Study completion31 Aug 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for CancerStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 150 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07751783
Sponsor's protocol ID: KMUHIRB-F(I)-20260064
Status last verified: Jul 2026
First submitted: 3 Aug 2026
Last updated: 7 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: There is no plan to share individual participant data (IPD) in order to maintain participant privacy and confidentiality